Third Generation CAR T cells For Relapsed Lymphoma and Leukemia

Angelica Loskog, PhD Professor of Immunotherapy (adjunct) Dept of Immunology, Genetics and Pathology Uppsala University Uppsala SwedenMedicalResearch.com Interview with:
Angelica Loskog, PhD
Professor of Immunotherapy (adjunct)
Dept of Immunology, Genetics and Pathology
Uppsala University
Uppsala Sweden

Medical Research: What is the background for this study? What are the main findings?

Dr. Loskog: CAR T cells have shown remarkable effect in patients with B cell malignancy in the US using 2nd generation CAR T cells. Acute leukemia (ALL) seems easier to treat than lymphomas and one of the reasons may be difficulties for CAR T cells to penetrate a solid lesion or due to a higher local presence of immunosuppressive cells within a lesion. As one of the first centers outside US we are evaluating 3rd generation CAR T cells in both lymphoma and ALL aiming to compare the responses and investigating biological reasons for the different responses. So far we have treated 11 patients and 6 of them had initial complete responses. Unfortunately, some progressed later.

Medical Research: What should clinicians and patients take away from your report?

Dr. Loskog: It is possible to achieve complete responses also in lymphoma with low doses of preconditioning only. However, for sustained effect it may be necessary to give the patients supportive treatment also after T cell infusion that keep the level of suppressive immune cells low. There is great promise in CAR T cell therapy but we are yet to define the best protocol to achieve longterm complete responses in lymphoma patients.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Loskog: We are currently investigating the immunosuppressive environment in the patients before and after CAR T cell therapy and initial data support increasing immunosuppression with time. A supportive treatment given after CAR T cell infusion needs to reduce suppressive immune cells at the same time leaving CAR T cells active. Finding and testing such drugs to be used together with CAR T cell therapy, or immunotherapy in general, is a crucial task for the future.

Citation: CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference: Sept 2015

Abstract 041 CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia report from the Swedish phase I/IIa trial. Gunilla Enblad, Hannah Karlsson, Kristina I Wikstrom,

Magnus Essand, Barbara Savoldo, Malcolm K Brenner, Gianpietro Dotti, Martin Hoglund, Hans Hagberg, Angelica Loskog.

MedicalResearch.com is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Angelica Loskog, PhD (2015). CAR T cells For Relapsed Lymphoma and Leukemia MedicalResearch.com

Angelica Loskog, PhD (2015). Third Generation CAR T cells For Relapsed Lymphoma and Leukemia 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.